Q-omics provides the consensus-scored UBTFL2 profile across patient tissues and cancer cell-line models. UBTFL2 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, UBTFL2 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, UBTFL2 RNA expression shows 6,304 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, BRCA, and STAD as cancer lineages where UBTFL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBTFL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBTFL2 survival associations across molecular data types. UBTFL2 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBTFL2 RNA expression–survival associations across cancer types. High UBTFL2 expression shows unfavorable associations in KIRP, LUSC, DLBC, SKCM, UCEC and STAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for UBTFL2 RNA expression.
This table summarizes UBTFL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for UBTFL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBTFL2 shows higher tumor expression in BRCA and LUSC. The BRCA box plot shows higher UBTFL2 RNA expression in tumor versus normal tissue (log2 FC = +0.006, t-test p = .041).
This table shows molecular features associated with UBTFL2 in patient tissues and cancer cell lines. In patient samples, UBTFL2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
